SCHEMBL166469

SCHEMBL166469

O=CC(Br)c1ccccc1Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37
HTT P42858 1/20 0.36
HSD11B1 P28845 4/20 0.34
CYP2C19 P33261 3/20 0.34
CYP2C9 P11712 2/20 0.34
ALDH1A1 P00352 4/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX15 P16050 1/20 0.33
IKBKB O14920 1/20 0.32
DYRK2 Q92630 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA4 P22748 1/20 0.32
CA6 P23280 1/20 0.32
GAA P10253 1/20 0.31
CYP1A2 P05177 1/20 0.31
OPRL1 P41146 1/20 0.31
PLCG1 P19174 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21495057 1.00 IDO1 (0.37) IDO1TDO2HTTHSD11B1CYP2C19
SCHEMBL5949824 0.79 PARP1 (0.39) CYP2C19CYP2C9ALDH1A1CYP1A2
SCHEMBL2559434 0.79 IDO1 (0.38) IDO1TDO2HTTHSD11B1CYP2C19
SCHEMBL22445604 0.76 IDO1 (0.40) IDO1TDO2HTTHSD11B1CYP2C19
SCHEMBL22445608 0.76 ACP3 (0.39) IDO1TDO2CYP2C19CYP2C9ALDH1A1
SCHEMBL4053545 0.76 ALDH1A1 (0.30) CYP2C19CYP2C9ALDH1A1CYP1A2
SCHEMBL1701143 0.76 GABRA1 (0.46) ALDH1A1CYP3A4ALOX15CA2CA4
SCHEMBL20551403 0.76 CES2 (0.40) IDO1TDO2CYP2C9ALDH1A1CYP3A4
SCHEMBL166430 0.76 CES2 (0.40) IDO1TDO2CYP2C9ALDH1A1CYP3A4
SCHEMBL38142 0.76 ACP3 (0.39) IDO1TDO2CYP2C19CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856737-A1 HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2021-08-04 EP disclosed
WO-2020064792-A1 HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2020-04-02 WO disclosed
EP-2534154-A1 MACROCYCLES AS FACTOR XIA INHIBITORS Bristol-Myers Squibb Company (US) 2012-12-19 EP disclosed
EP-2534152-A1 MACROCYCLES AS FACTOR XIA INHIBITORS Bristol-Myers Squibb Company (US) 2012-12-19 EP disclosed
WO-2012027965-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed
WO-2011151434-A1 NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS EUROSCREEN S.A. (BE) 2011-12-08 WO disclosed
WO-2011100402-A1 MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-08-18 WO disclosed
WO-2011100401-A1 MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-08-18 WO disclosed
WO-2011037731-A1 BORON CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2011-03-31 WO disclosed
EP-2285384-A2 BORON-CONTAINING SMALL MOLECULES Anacor Pharmaceuticals, Inc. (US) 2011-02-23 EP disclosed
EP-2164331-A1 BORON-CONTAINING SMALL MOLECULES Anacor Pharmaceuticals, Inc. (US) 2010-03-24 EP disclosed
WO-2009140309-A2 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2009-11-19 WO disclosed
WO-2008157726-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2008-12-24 WO disclosed
EP-1359913-A1 THROMBIN INHIBITORS Merck & Co., Inc. (US) 2003-11-12 EP disclosed
WO-2002064140-A1 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-08-22 WO disclosed
EP-0654030-A1 IMIDAZOLE DERIVATIVES HAVING A II ANTAGONIST ACTIVITY. LUSO FARMACO INST (IT) 1995-05-24 EP disclosed